HEALTHY EXTRACTS INC.
A growing nutraceutical manufacturer in North America leveraging operational cash flow to fuel expansion amidst a competitive wellness supplement market.
A growing nutraceutical manufacturer in North America leveraging operational cash flow to fuel expansion amidst a competitive wellness supplement market.
Investors might consider HYEX for its improving operational efficiency, evidenced by positive cash flow from operations and a deliberate reduction in inventory levels which lowers risk. The company's dual revenue model through private label manufacturing and proprietary brands offers multiple avenues for growth as the global nutraceutical market expands rapidly. If management can successfully scale production and drive down unit costs, the current losses could be viewed as an investment in future market share rather than a fundamental flaw.
The stock carries significant risk due to a substantial net loss of $840k and a deep retained earnings deficit of over $19M, suggesting the business model may not yet be self-sustaining. High operating expenses consuming most of the gross profit indicate potential structural inefficiencies that could persist even as revenue grows. With limited cash reserves relative to liabilities and negative financing cash flow, the company faces liquidity challenges that could threaten operations if external capital drying up.
Healthy Extracts Inc. (HYEX) is a North American nutraceutical manufacturer specializing in premium botanical supplements and wellness extracts. The company serves health-conscious consumers across the US market through direct-to-consumer channels and retail partnerships, focusing on high-margin natural product formulations. Recent financials highlight a strong rebound in operations cash flow despite ongoing net losses driven by significant cost of revenue and general administrative expenses.
Management successfully stabilized cash flow from operations at $282k while significantly reducing inventory by $265k, suggesting a strategic pivot toward leaner operations. However, the company continues to burn capital with a net loss of $841k, driven largely by high operating expenses that exceed gross profit, requiring careful monitoring of cost controls. The substantial cash outflow from financing activities indicates reliance on equity or debt issuance to fund these losses and balance sheet adjustments.
The global nutraceuticals industry is projected to grow at a robust CAGR driven by shifting consumer preferences toward natural health solutions and personalized wellness products. This sector benefits from recurring revenue models through subscription-based supplements and high customer lifetime values once brand loyalty is established. However, it remains vulnerable to regulatory changes regarding ingredient claims and intense price competition that can compress margins for smaller manufacturers.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.3M | $2.5M | $3.1M |
| Cost of Revenue | $880.0K | $864.1K | $1.2M |
| Gross Profit | $1.4M | $1.6M | $1.9M |
| Operating Expenses | $2.3M | $3.9M | $2.1M |
| Operating Income | $-911.6K | $-2.2M | $-183.1K |
| G&A | $2.3M | $3.9M | $2.1M |
| Stock-Based Comp | $0 | — | — |
| Other OpEx | $-63.7K | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-911.6K | $-2.2M | $-183.1K |
| Income Tax | $71.5K | $0 | $0 |
| Continuing Ops | $-983.1K | $-2.2M | $-183.1K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-983.1K | $-2.5M | $-840.7K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-983.1K | $-2.5M | $-840.7K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $2.0M | $1.9M | $1.7M |
| Accounts Receivable | $105.8K | $30.4K | $11.0K |
| Inventory | $1.8M | $1.6M | $1.4M |
| Other Current Assets | $65.7K | $243.0K | $287.2K |
| Long-Term Assets | $790.5K | $735.3K | $718.6K |
| Goodwill | $193.3K | $193.3K | $193.3K |
| Operating Leases | — | $71.6K | $9.0K |
| Other LT Assets | $597.3K | $470.5K | $516.3K |
| Total Assets | $2.8M | $2.6M | $2.4M |
| Current Liabilities | $902.8K | $1.7M | $2.0M |
| Accounts Payable | $91.3K | $116.8K | $52.2K |
| Current Leases | — | $65.2K | $9.2K |
| Other Current Liab | $716.9K | $1.3M | $1.7M |
| Long-Term Liabilities | $0 | $0 | $0 |
| LT Operating Leases | — | $9.2K | $0 |
| Other LT Liab | — | $-9.2K | $0 |
| Total Liabilities | $902.8K | $1.7M | $2.0M |
| Shareholders' Equity | $1.9M | $954.6K | $410.4K |
| Paid-In Capital | $17.5M | $19.0M | $19.3M |
| Retained Earnings | $-15.9M | $-18.4M | $-19.2M |
| Treasury Stock | — | — | $5.4K |
| Total L&E | $2.8M | $2.6M | $2.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-983.1K | $-2.5M | $-840.7K |
| Non-Cash Adjustments | $738.4K | $2.0M | $936.5K |
| Working Capital Changes | $-90.2K | $24.4K | $186.2K |
| Cash from Operations | $-335.0K | $-415.7K | $282.0K |
| Capital Expenditures | $8.0K | $0 | — |
| Cash from Investing | $-8.0K | $0 | $0 |
| Cash from Financing | $186.5K | $369.5K | $-189.4K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-156.4K | $-46.2K | $92.6K |
| Beginning Cash | $222.1K | $65.7K | $19.4K |
| Ending Cash | $65.7K | $19.4K | $112.0K |
1) Premium Botanical Extracts: High-margin manufacturing and private labeling of herbal supplements for distributors and retail partners. 2) Direct-to-Consumer Brand Portfolio: Proprietary supplement lines sold online targeting specific wellness niches like sleep, immunity, and vitality. 3) Private Label Manufacturing: Contract manufacturing services providing formulation development and production for third-party brands seeking to enter the nutraceutical space.
1) Persistent Net Losses: The company reported a net loss of $840k, with accumulated retained earnings deficits exceeding $19M, raising concerns about long-term sustainability without significant profitability improvements. 2) High Operating Expenses: General and administrative expenses ($2.1M) nearly match gross profit margins, indicating potential inefficiencies or aggressive investment in growth that may not yet be paying off. 3) Working Capital Constraints: The company has a negative working capital position relative to its current liabilities, relying heavily on financing cash outflows of $189k to maintain operations. 4) Market Competition: The nutraceutical sector is highly fragmented and competitive, with low barriers to entry that could erode margins if the company cannot differentiate its product offerings.
1) Operational Cash Flow Generation: Despite net losses, the company generated $281k in cash from operations, indicating strong core business liquidity and efficient working capital management. 2) Strategic Inventory Management: A significant reduction in inventory levels suggests effective supply chain optimization or a shift toward just-in-time manufacturing to reduce holding costs. 3) Scalable Manufacturing Infrastructure: The ability to serve both private label clients and proprietary brands creates dual revenue streams that can be leveraged for economies of scale as volume grows.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.